| Literature DB >> 32148547 |
Nur Shafika Mohd Sairazi1, K N S Sirajudeen2,3.
Abstract
In recent years, natural products, which originate from plants, animals, and fungi, together with their bioactive compounds have been intensively explored and studied for their therapeutic potentials for various diseases such as cardiovascular, diabetes, hypertension, reproductive, cancer, and neurodegenerative diseases. Neurodegenerative diseases, including Alzheimer's disease, Huntington's disease, Parkinson's disease, and amyotrophic lateral sclerosis are characterized by the progressive dysfunction and loss of neuronal structure and function that resulted in the neuronal cell death. Since the multifactorial pathological mechanisms are associated with neurodegeneration, targeting multiple mechanisms of actions and neuroprotection approach, which involves preventing cell death and restoring the function to damaged neurons, could be promising strategies for the prevention and therapeutic of neurodegenerative diseases. Natural products have emerged as potential neuroprotective agents for the treatment of neurodegenerative diseases. This review focused on the therapeutic potential of natural products and their bioactive compounds to exert a neuroprotective effect on the pathologies of neurodegenerative diseases.Entities:
Year: 2020 PMID: 32148547 PMCID: PMC7042511 DOI: 10.1155/2020/6565396
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1Various types of mechanisms have been associated with the neurodegeneration that implicated in the progression and pathogenesis of neurodegenerative diseases.
Figure 2The potential therapeutic targets on various mechanisms of neurodegeneration.
Natural products and their bioactive compounds with neuroprotective activities in treating Parkinson's disease.
| Plant extracts/phytochemicals (plant source)/natural products/substances | Study model | Neuroprotective activities | References |
|---|---|---|---|
| Arctigenin extracted from | Rotenone-induced rats | (i) Improved behavioral changes | [ |
| (ii) Decreased dopaminergic neuronal loss in the substantia nigra pars compacta | |||
| (iii) Decreased | |||
| (iv) Increased GSH and activities of superoxide dismutase and glutathione peroxidase | |||
| (v) Decreased malondialdehyde level | |||
| (vi) Decreased inflammatory markers (TNF- | |||
| (vii) Decreased NF- | |||
| (viii) Reduced GFAP and Iba-1 expressions | |||
|
| |||
|
| MPTP-induced mouse | (i) Ameliorated MPTP-induced behavioral impairment | [ |
| (ii) Attenuated oxidative stress | |||
| (iii) Decreased monoamine oxidase activity | |||
| (iv) Protected dopaminergic neurons | |||
|
| |||
|
| Rotenone-induced mouse | (i) Restored the rotenone-induced motor and nonmotor behavioral deficits | [ |
| (ii) Attenuated oxidative stress by decreasing TBARS level and increasing GSH level and superoxide dismutase, catalase, and glutathione peroxidase activities | |||
| (iii) Attenuated neuroinflammation markers (TNF- | |||
| (iv) Decreased NF- | |||
| (v) Increased BDNF expression in the substantia nigra pars compacta | |||
| (vi) Attenuated the decrease in tyrosine hydroxylase expression in the substantia nigra pars compacta | |||
| (vii) Attenuated the depletion of striatal dopamine level | |||
|
| |||
| Dihydromyricetin (DHM) (a natural flavonoid extracted from | MPTP-induced mouse | (i) Attenuated MPTP-induced mouse behavioral impairments and dopaminergic neuron loss | [ |
| (ii) Attenuated the MPTP-induced deficit in movement balance | |||
| (iii) Improved exploratory and locomotor activity | |||
| (iv) Attenuated the decrease in tyrosine hydroxylase and vesicular monoamine transporter 2 expression in the striatum and substantia nigra pars compacta | |||
|
| |||
| Agaropentaose, agaro-oligosaccharide monomer which is hydrolysates of agarose isolated from red algae | 6-ODHA-induced neurotoxicity in SH-SY5Y cells | (i) Reduced intracellular ROS level | [ |
| (ii) Inhibited loss of mitochondrial membrane potential | |||
| (iii) Inhibited the activation of NF- | |||
| (iv) Enhanced the activities of superoxide dismutase, glutathione reductase, glutathione peroxidase | |||
| (v) Reduced malondialdehyde level | |||
| (vi) Reduced the number of apoptotic cells | |||
| (vii) Suppressed the cleaved of caspase 3 | |||
| (viii) Decreased the Bax/Bcl-2 ratio | |||
|
| |||
| Boswellic acids | Rotenone-induced rats | (i) Increased motor functions | [ |
| (ii) Ameliorated percent of degenerating neuronal in the substantia nigra pars compacta | |||
| (iii) Increased percent of viable neurons in the substantia nigra pars compacta | |||
| (iv) Reduced inflammatory markers (TNF- | |||
| (v) Decreased NF- | |||
| (vi) Increased striatal dopamine level | |||
| (vii) Increased nigral tyrosine hydroxylase immunostaining | |||
|
| |||
|
| Rotenone-induced mouse | (i) Inhibited the increase of brain malondialdehyde and nitric oxide levels | [ |
| (ii) Restored brain GSH level and paraoxonase-1 (PON1) activity | |||
| (iii) Attenuated the increase in brain 5-lipoxygenase activity | |||
| (iv) Restored brain cholinesterase activity | |||
| (v) Decreased GFAP-positive immunoreactivity in the cerebral cortex | |||
| (vi) Prevented the neuronal degeneration in the substantial nigra, cerebral cortex, and hippocampus | |||
|
| |||
|
| MPTP-induced neurotoxicity in mouse and glutamate-induced excitotoxicity in primary cortical neuron cultures | (i) Inhibited glutamate-induced excitotoxicity in vitro | [ |
| (ii) Inhibited glutamate-induced in the decrease of phosphorylated Akt and Bcl-2 | |||
| (iii) Prevented dopaminergic neuronal loss | |||
|
| |||
| Curcuminoids ( | MPTP-induced mouse | (i) Prevented the depletion of dopamine and tyrosine hydroxylase immunoreactivity | [ |
| (ii) Reversed GFAP and iNOS protein expressions | |||
| (iii) Reduced proinflammatory cytokine and total nitrite generation in the striatum | |||
| (iv) Improved motor performance and gross behavioral activity, as determined by rotarod and open field tests | |||
|
| |||
|
| Rotenone-induced rats | (i) Rescued dopaminergic neurons | [ |
| (ii) Prevented dopaminergic neuronal loss in the substantia nigra and striatal dopamine fibers | |||
| (iii) Reduced Iba-1 and GFAP expressions | |||
| (iv) Decreased the number of activated astrocytes and microglia | |||
| (v) Attenuated proinflammatory cytokines (IL-1b, IL-6, and TNF- | |||
| (vi) Restored antioxidant enzymes and glutathione depletion | |||
| (vii) Inhibited lipid peroxidation | |||
|
| |||
| Fish oil supplementation (rich in omega-3 polyunsaturated fatty acids) | 6-OHDA-induced rats | (i) Mitigated the loss of substantia nigra neurons and nerve terminals in the striatum | [ |
| (ii) Reduced the density of iNOS-immunoreactive cells and microglia (OX-42) and astrocyte (GFAP) reactivity | |||
|
| |||
| Germinated brown rice | Rotenone-induced rats | (i) Enhanced the motor activity in rotenone-induced rats | [ |
| (ii) Decreased serum and brain TNF- | |||
| (iii) Attenuated the dopaminergic neuronal cell loss | |||
| (iv) Attenuated histopathological changes in substantia nigra neurons with visible nuclei and | |||
| (v) Increased the number of surviving dopaminergic neurons | |||
| (vi) Decreased the number of apoptotic cells | |||
| (vii) Increased the number of viable cells | |||
| (viii) Decreased TNF- | |||
|
| |||
|
| MPTP-induced mouse | (i) Improved memory retention and retrieval | [ |
|
| |||
| Olive leaf extract ( | Rotenone-induced rats | (i) Suppressed oxidative stress by decreasing lipid peroxidation level and increasing midbrain antioxidant enzymes activities | [ |
| (ii) Inhibited the depletion of tyrosine hydroxylase-positive neurons | |||
|
| |||
| Puerarin (an active component of | MPTP-induced mouse | (i) Attenuated MPTP-induced behavioral deficits, dopaminergic neuronal degeneration, and dopamine depletion | [ |
| (ii) Enhanced glutathione activity, glial cell line-derived neurotrophic factor (GDNF) expression, and PI3K/Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of ROS formation in mouse | |||
| (iii) Ameliorated MPTP-reduced lysosome-associated membrane protein type 2A (Lamp 2A) expression | |||
|
| |||
| Rosmarinic acid isolated from callus of | 6-OHDA-induced rats | (i) Restored the striatal dopamine level | [ |
| (ii) Increased the number of tyrosine hydroxylase | |||
| (iii) Decreased the iron level in the substantia nigra | |||
| (iv) Upregulated the ratio of Bcl-2/Bax gene expression in the substantia nigra | |||
|
| |||
|
| MPTP-induced mouse | (i) Alleviated MPTP-induced motor deficits | [ |
| (ii) Attenuated the decrease in the number of tyrosine hydroxylase-positive neurons in the substantia nigra | |||
| (iii) Restored the depletion of striatal dopamine level | |||
| (iv) Restored GSH level and antioxidant enzyme activities and decreased lipid peroxidation in the striatum | |||
| (v) Decreased the expression of | |||
|
| |||
|
| 6-OHDA-induced rats | (i) Increased the dopamine levels and complex I activity | [ |
| (ii) Attenuated iron asymmetry ratio | |||
| (iii) Reduced oxidative stress | |||
| (iv) Restored 6-OHDA-induced behavioral changes in locomotor activity | |||
| (v) Reduced the degree of catalepsy | |||
| (vi) Increased the time of fall in rotarod test | |||
|
| |||
|
| Rotenone-induced mouse | (i) Ameliorated motor dysfunction | [ |
| (ii) Increased the percentage of viable neurons | |||
| (iii) Increased the number of tyrosine hydroxylase | |||
| (iv) Attenuate inflammatory markers (iNOS and COX-2 mRNA expression) | |||
| (v) Reduced DNA damage markers (8-oxo-2′-deoxyquanosine and MTH1 expression) | |||
| (vi) Suppressed oxidative stress by increasing GSH and activities of superoxide dismutase and catalase and decreasing malondialdehyde level | |||
| (vii) Downregulated CD11b mRNA expression (microglia marker) | |||
| (viii) Improved striatal dopamine level | |||
|
| |||
| Ethyl acetate fraction of | MPTP-induced rats | (i) Improved the motor function and oxidative defense alteration | [ |
| (ii) Decreased the increased concentration of lipid peroxidation and nitrite concentration | |||
| (iii) Restored the decreased GSH level and activity of catalase | |||
| (iv) Attenuated the proinflammatory cytokines (TNF- | |||
| (v) Restored the level of dopamine and its metabolites | |||
| (vi) Protected the dopaminergic neurons | |||
|
| |||
|
| Paraquat-induced rats | (i) Decreased lipid peroxidation and protein oxidation | [ |
| (ii) Increased level of GSH and the activities of antioxidant enzymes | |||
| (iii) Prevented neuronal damage | |||
Natural products and their bioactive compounds with neuroprotective activities in treating Alzheimer's disease.
| Plant extracts/phytochemicals (plant source)/natural products/substances | Study model | Neuroprotective activities | References |
|---|---|---|---|
| Turmeric (powdered rhizome of | Case studies of 3 patients with progressive dementia | (i) Improvement in the behavioral symptoms and quality of life | [ |
|
| |||
| Coconut oil enriched Mediterranean diet | 44 patients with Alzheimer's disease | (i) improved the cognitive functions | [ |
|
| |||
| Germinated brown rice (Malaysian mixed varieties; MR219 and MR220) | A | (i) Reduced intracellular ROS generation | [ |
| (ii) Attenuated A | |||
|
| |||
| Huperzine A isolated from | Hypoxic-ischemic and glutamate-induced brain injury and cytotoxicity | (i) Reduce A | [ |
| (ii) Decrease oxidative damage | |||
| (iii) Protects neurons from cytotoxic and apoptosis | |||
| (iv) Inhibited the glutamate toxicity | |||
|
| |||
| Huperzine A isolated from | 50 patients with Alzheimer's disease | (i) Improvement in memory, cognitive, and behavior functions | [ |
|
| |||
| Methanolic extract of | A | (i) Ameliorated cognitive impairment and memory deficits | [ |
| (ii) Decreased acetylcholinesterase activity | |||
| (iii) Restored the level of GSH and the activities of antioxidant enzymes (superoxide dismutase and glutathione peroxidase) | |||
| (iv) Decreased the lipid peroxidation and protein oxidation level | |||
| (v) Attenuated hippocampal apoptosis by lowering the enrichment factor of apoptosis level | |||
| (v) Increased BDNF mRNA copy number | |||
| (vi) Decreased IL-1 | |||
|
| |||
| Osmotin, a plant protein extracted from | A | (i) Reversed synaptic deficits | [ |
| (ii) Attenuated A | |||
| (iii) Increased spontaneous alternation behavior | |||
| (iv) Ameliorated memory impairment in a | |||
| (v) Alleviated the hyperphosphorylation of the tau protein at serine 413 through the regulation of the aberrant phosphorylation of p-PI3K, p-Akt (serine 473), and p-GSK3 | |||
| (vi) Prevented A | |||
| (vii) Attenuated A | |||
|
| |||
| Safflower yellow (natural safflower aqueous extract) | A | (i) Improved short- and long-term memory of rats | [ |
| (ii) Decreased inflammatory markers (iNOS, IL-1 | |||
| (iii) Reduced neuronal cell loss in the hippocampus and cortex | |||
| (iv) Inhibited the activation of glial cells | |||
| (v) Downregulated M1 microglial markers (iNOS and CD86) | |||
| (vi) Upregulated M2 microglial markers (arginase-1, CD2066, and YM-1) | |||
|
| |||
|
| A | (i) Prevented memory loss | [ |
| (ii) Decreased lipid peroxidation | |||
| (iii) Increased neuronal density in the hippocampus | |||
|
| |||
| Yacon ( | A | (i) Decreased oxidative stress in the hippocampus | [ |
| (ii) Prevented memory deficits | |||
| (iii) Attenuated the hippocampal damage | |||
Natural products and their bioactive compounds with neuroprotective activities in treating amyotrophic lateral sclerosis and multiple sclerosis as well as chronic inflammation.
| Plant extracts/phytochemicals (plant source)/natural products/substances | Study model | Neuroprotective activities | References |
|---|---|---|---|
| Anthocyanin extracted from strawberries | G93A mutant human SOD1 (hSOD1G93A) mouse model of amyotrophic lateral sclerosis | (i) Delayed the onset of disease and extend survival of hSOD1G93A mouse | [ |
| (ii) Preserved hind limb grip strength in the hSOD1G93A mouse | |||
| (iii) Reduced astrogliosis (GFAP) in the spinal cord of hSOD1G93A mouse | |||
| (iv) Preserved neuromuscular junctions in gastrocnemius muscle tissue | |||
|
| |||
|
| Experimental autoimmune encephalomyelitis mouse model of multiple sclerosis | (i) Reduced the symptoms in the experimental autoimmune encephalomyelitis mouse | [ |
| (ii) Reduced demyelination in the spinal cord | |||
| (iii) Reduced inflammation (IFN- | |||
| (iv) Reduced gliosis in the spinal cord | |||
| (v) Alleviated T helper (Th)1/Th17 response | |||
| (vi) Reduced immune cell infiltration into spinal cord and brain | |||
|
| |||
| Isogarcinol extracted from | Experimental autoimmune encephalomyelitis-induced mouse | (i) Alleviated inflammation and demyelination in the brain and spinal cord | [ |
| (ii) Ameliorated the clinical signs of experimental autoimmune encephalomyelitis-induced mouse | |||
| (iii) Reduced intracranial lesions | |||
| (iv) Reduced number of Th1 and Th17 cells differentiation by inhibiting Janus kinase (JAK)/signal transducers and activators of transcription (STAT) signaling pathway | |||
| (v) Reduced activation of CD4+ and CD11b+ cell populations | |||
|
| |||
|
| Experimental autoimmune encephalomyelitis-induced rats | (i) Reduced inflammatory markers (TNF- | [ |
| (ii) Ameliorated the clinical signs of experimental autoimmune encephalomyelitis-induced rats | |||
| (iii) Suppressed T-cell proliferation | |||
| (iv) Ameliorated experimental autoimmune encephalomyelitis-induced paralysis | |||
|
| |||
|
| Experimental autoimmune encephalomyelitis-induced rats | (i) Decreased transforming growth factor beta-1 (TGF- | [ |
| (ii) Enhanced remyelination in the cerebellum | |||
| (iii) Suppressed inflammation | |||
|
| |||
|
| Experimental autoimmune encephalomyelitis-induced mouse | (i) Reduced inflammation and demyelination in spinal cords | [ |
| (ii) Reduced CD3+ and CD11b+ cell populations in the spinal cord and brain | |||
| (iii) Ameliorated the clinical signs | |||
| (iv) Inhibited NF- | |||
| (v) Reduced expression of iNOS and NADPH oxidase | |||
| (vi) Reduced peroxynitrite level in spinal cords | |||
|
| |||
| White grape ( | Experimental autoimmune encephalomyelitis-induced mouse | (i) Reduced TNF- | [ |
| (ii) Reduced nitrotyrosine level | |||
| (iii) Inhibited apoptosis (caspase-3 and Bcl-2 expression) | |||
| (iv) Decreased the number of terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)-positive | |||
| (v) Modulated transcription factor Fork head box P3 | |||
|
| |||
| Walnut extract | Lipopolysaccharide-induced neurotoxicity in rat microglial cell line | (i) Downregulated iNOS and Iba-1 expressions | [ |
| (ii) Upregulated calmodulin expression | |||
Natural products and their bioactive compounds with neuroprotective activities in treating other neurodegenerative diseases and neurological disorders.
| Plant extracts/phytochemicals (plant source)/natural products/substances | Study model | Neuroprotective activities | References |
|---|---|---|---|
| Ethanolic extract of | Strychnine-induced convulsions in albino rats | (i) Exhibited anticonvulsant activity by delaying the onset convulsion | [ |
| (ii) Maintained the structure of neurons | |||
| (ii) Decreased neuronal apoptosis | |||
|
| |||
|
| A combination of | (i) Improved learning and memory in aging mouse | [ |
| (ii) Upregulated mRNA expression of BDNF and fibroblast growth factor 2 (FGF2) in the hippocampus of aging mouse | |||
| (iii) Inhibited mRNA expression of neuroinflammatory factors (TNF- | |||
| (iv) Activated PI3K/Akt signaling pathway | |||
| (v) Inhibited the canonical caspase-3 apoptosis pathways | |||
|
| |||
| Methanolic extract of C | Maximal electroshock-induced seizures in albino Wistar rats | (i) Exhibited the anticonvulsant activity in maximal electroshock-induced seizures by reducing epileptic seizures | [ |
| (ii) Increased gamma-aminobutyric acid (GABA) release | |||
| (iii) Decreased lipid peroxidation and acetylcholinesterase activity | |||
| (iv) Increased GSH level | |||
|
| |||
|
| Pentylenetetrazol-kindled mouse | (i) Reduced seizures and cortical malondialdehyde level | [ |
| (ii) Enhanced cortical GSH | |||
| (iii) Reduced the percentage of pyknotic neurons in the hippocampus | |||
| (iv) Increased the percentage of viable neurons | |||
|
| |||
| Parawixin 10, a compound isolated from | A rat excitotoxicity model of brain injury by kainic acid, N-methyl-D-aspartate, and pentylenetetrazol | (i) Decreased glial proliferation in all hippocampal subfields studied, as well as the preservation of cell layers | [ |
| (ii) Prevented the onset of seizures induced with kainic acid, N-methyl-D-aspartate, and pentylenetetrazol | |||
| (iii) Increased the latency to the onset of kainic acid-, pentylenetetrazol-, and N-methyl-D-aspartate-induced seizures | |||
|
| |||
| White rose ( | Kainic acid-induced mouse and in HB1.F3 human neural stem cells | (i) Exhibited radical scavenging activities | [ |
| (ii) Inhibited lipid peroxidation | |||
| (iii) Decreased scores of epileptiform seizures | |||
| (iv) Decreased hippocampal pyramidal neuronal loss | |||
| (v) Downregulated mRNA expressions of antioxidant enzymes | |||
| (vi) Downregulated mRNA and protein expressions of inflammatory mediators | |||
|
| |||
| Rosemary extract | Kainic acid-induced rats | (i) Decreased neuronal loss in CA3 hippocampal region | [ |
| (ii) Decreased spatial memory and learning impairment | |||
|
| |||
| Walnut extract | Lipopolysaccharide-induced neurotoxicity in rat microglial cell line | (i) Downregulated iNOS and Iba-1 expressions | [ |
| (ii) Upregulated calmodulin expression | |||
Taken together, these findings proposed that the natural products and their bioactive compounds may have a potential neuroprotective effect against neurodegenerative disease through various mechanisms, primarily through their antioxidant, anti-inflammatory, and antiapoptotic. This signifies the therapeutic evidence of the natural products and their bioactive compounds as neuroprotective agents.